Phase 2 Trial Shows Dalantercept Has Limited Effectiveness in Ovarian Cancer Patients

Phase 2 Trial Shows Dalantercept Has Limited Effectiveness in Ovarian Cancer Patients
A Phase 2 clinical trial determined that treatment with dalantercept, an inhibitor of blood vessel maturation, is safe but has limited effectiveness in ovarian cancer patients, none of whom responded to the investigational therapy. The clinical development of the investigational therapy has been discontinued. Trial findings were published in the study, “Phase II evaluation of dalantercept in

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *